The Sociology Behind Data Silos In Pharma R & D

From the perspective of those responsible for delivering the primary data analysis – the original reason the data were collected – there is generally no perceptible upside for investing precious and limited time and capital (and quite perceptible downsides) in high-falutin data initiatives.

Source: Forbes.com Healthcare News - May 31, 2019 Category: Pharmaceuticals Authors: David Shaywitz, Contributor Source Type: news